Ablexis Announces Licensing of the AlivaMab Mouse to NGM Biopharmaceuticals

BURLINGAME, Calif., Jan. 04, 2018 -- Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with NGM Biopharmaceuticals, Inc. The non-exclusive license grants NGM rights to use the AlivaMab Mouse for antibody drug discovery and development.

“Ablexis is pleased to add NGM to the list of leading biopharmaceutical companies that are using the AlivaMab Mouse,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “The AlivaMab Mouse is already being used by the majority of the world’s top 15 pharmaceutical companies, more than any other next generation antibody discovery platform. Ablexis’ greater licensing flexibility is supporting our continuing mission to expand licensing of the AlivaMab Mouse for the rapid and efficient discovery of antibody drug candidates that meet target product profiles for activity, specificity and developability.”

About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple companies and continues making the AlivaMab Mouse available via non-exclusive licenses. More information can be found by visiting the Company’s website at www.ablexis.com.

Ablexis Corporate Contact:
Ablexis, LLC
Larry Green, (415) 967-1220
[email protected] 

Ablexis Media Contact:
Red House Communications
Denise Powell, (510) 703-9491
[email protected]